Biologics
-
Biologics
Steady Growth Forecast for Global Orthobiologics Market
Increasing prevalence of bone diseases is expected to fuel the sector's growth.Michael Barbella, Managing Editor 02.06.23
-
Biologics | Large Joint
Orthogen's IDE Trial for Knee OA Gets FDA Nod
Orthogen to launch pivotal trial of novel therapy for knee osteoarthritis.Sam Brusco, Associate Editor 01.18.23
-
Biologics | Large Joint
Lipogems Begins ARISE IDE Study for Knee OA
Will compare its MicroFat autologous, intra-articular injection versus corticosteroid injection to treat knee osteoarthritis (OA).Sam Brusco, Associate Editor 01.16.23
-
Biologics
Researchers Develop Hydrogel Injections to Treat Antibiotic-Resistant Infections
Can suppress infections and encourage healing around prosthetics without the problems caused by antibiotics and tissue grafting.Charles Sternberg, Associate Editor 01.10.23
-
Biologics | Spine/Neurology
Paul Mraz Appointed President and CEO of FzioMed
Most recently, Mraz was president and CEO of ApiFix Ltd.Michael Barbella, Managing Editor 01.09.23
-
Biologics | Spine/Neurology
OssDsign Catalyst 6-Month Study Results Revealed
First-in-patient case report of OssDsign Catalyst shows complete spinal fusion 6 months post-surgery.Sam Brusco, Associate Editor 01.04.23
-
Biologics
Novadip Biosciences Shares Positive Results from Phase 1/2 Clinical Trial Evaluating NVD-003
Results demonstrate NVD-003 has a favorable safety profile and convincing efficacy in patients following failure of conventional treatment.Charles Sternberg, Associate Editor 12.12.22
-
Biologics
Biogennix Marks Milestone With its DirectCell Advanced Bone Grafting System
The DirectCell System provides surgeons two methods of collecting bone marrow derived stem cells.Michael Barbella, Managing Editor 11.30.22
-
Biologics
RevBio’s Tetranite Novel Bone Adhesive to Fly on SpaceX CRS-26
The company will examine how well Tetranite works to regenerate new bone during spaceflight.Charles Sternberg, Associate Editor 11.18.22
-
Biologics
Novadip Biosciences Raises Additional $39.1 Million
Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures.Charles Sternberg, Associate Editor 11.04.22
-
Biologics
BONESUPPORT’S CERAMENT G Used in First U.S. Patient Cases
Company received FDA authorization earlier this year for CERAMENT G in osteomyelitis management.Michael Barbella, Managing Editor 10.25.22
-
Biologics
Orthofix Reports First Patient Implants With Legacy Demineralized Bone Matrix
The putty can be used to treat traumatic injuries in the spine, pelvis, or extremities.Michael Barbella, Managing Editor 10.14.22
-
Biologics
Collagen Matrix Inc. Acquires Polyganics
The purchase expands Collagen Matrix's portfolio of bioresorbable solutions and technology platforms for bone and tissue repair.Charles Sternberg, Associate Editor 10.10.22
-
Biologics
Spinal Biomaterial Demonstrates Early Healing in Retrospective Study
Data show DiFusion's ZFUZE achieves 91.4% fusion rates at eight months.Michael Barbella, Managing Editor 10.06.22
-
Biologics
Ivory Dentin Graft Earns CE Mark
It's the first and only dentin graft, according to the company.Sam Brusco, Associate Editor 09.21.22
-
Biologics
FDA OKs Ventris Medical's Amplify Putty, Bone Graft Extender
Amplify is a synthetic bone graft biomaterial designed to optimize cell proliferation and bone formation.Sam Brusco, Associate Editor 09.13.22
-
Biologics
Ortho Regenerative Tech Changes Name to ChitogenX
Better represents company's proprietary tech platform expanded applications beyond orthopedics.Sam Brusco, Associate Editor 09.07.22
-
Biologics
Study: BONESUPPORT’s CERAMENT G Can Help Save Infected Limbs
Data show effectiveness of antibiotic-eluting bone graft substitute in managing bone infections.Michael Barbella, Managing Editor 08.19.22
-
Biologics
Six Orthopedic Firms En Route to Significant Market Disruption
The ODT Editors have spotlighted six companies outside the Top 10 they feel are making an impact on the device sector.08.12.22
-
Biologics
GreenBone Signs Distribution Agreement for its Regenerative Scaffold
Abiogen Pharma SpA will market the 3D bone substitute in Italy.Michael Barbella, Managing Editor 08.05.22
